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Portland, Me; and Salt Lake City, Utah
Objective: This meta-analysis was initiated to assess the efficacy and safety of anticoagulation therapy for adult patients
with isolated calf vein deep venous thrombosis (DVT).
Methods: We searched MEDLINE (1950-October 2010), the Cochrane Library (1993-October 2010), trial registries,
meeting abstracts, and selected references, using no limits. Included studies compared the results of anticoagulation
(vitamin K antagonist or therapeutic heparin) for a minimum of 30 days vs the results of no anticoagulation in adults with
calf vein DVT proved by ultrasound imaging or venograph who were monitored for at least 30 days. Two independent
reviewers extracted data using a piloted standardized form. Methodologic quality was assessed using the Cochrane Risk
of Bias tool for randomized controlled trials (RCTs) and the Newcastle-Ottawa Quality Assessment Scale for cohort and
case-control studies. Discrepancies were resolved by consensus or by a third reviewer. Authors were contacted for
additional information if necessary. Outcomes were pooled using Peto fixed-effects models.
Results: Of 2328 studies identified, two RCTs and six cohorts (126 patients treated with anticoagulation and 328
controls) met selection criteria. The methodologic quality of most studies was poor. Pulmonary embolism (PE; odds
ratio, 0.12; 95% confidence interval, 0.02-0.77; P  .03) and thrombus propagation (odds ratio, 0.29; 95% confidence
interval, 0.14-0.62; P  .04) were significantly less frequent in those who received anticoagulation. Significant
heterogeneity existed in studies reporting mortality rates, but these demonstrated a trend toward fewer deaths with
anticoagulation. When limited to randomized trials, the protective effect of anticoagulation for PE was no longer
statistically significant, but the benefit for preventing thrombus progression persisted. Adverse events such as bleeding
were sparsely reported but favored controls (P  .65).
Conclusions: Our review suggests that anticoagulation therapy for calf vein DVT may decrease the incidence of PE and
thrombus propagation. However, due to poor methodologic quality and few events among included studies for PE, this
finding is not robust. Thrombus propagation appears reduced with anticoagulation treatment. A rigorous RCTwill assist
in treatment decisions for calf vein DVT. (J Vasc Surg 2012;56:228-37.)
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aExtensive evidence supports anticoagulation for pa-
tients with proximal deep venous thrombosis (DVT) to
reduce death from pulmonary embolus (PE).1 No similar
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228onsensus exists for thrombosis of the deep veins of the
alf (cDVT).2 Proponents of anticoagulation for cDVT
ite the only randomized trial of anticoagulation for
DVT by Lagerstedt et al.3 This study demonstrated a
.5% nonfatal PE rate and 17% proximal thrombus ex-
ension rate in patients who did not receive anticoagula-
ion. Others eschew anticoagulation for cDVT, citing a
ow venous thrombotic event rate during surveillance of
DVTs.2
To date, published observational studies of cDVT are
nconsistent in their reporting of the risks associated with
ntreated cDVT: rates of PE and proximal extension range
rom 0% to 31%4-6 and 0% to 20%, respectively.5-8 Many of
hese studies report uncontrolled, single-center analyses of
ew patients. Risks associated with anticoagulation therapy
n these series are infrequently examined. Therefore, we
erformed a systematic review and meta-analysis of antico-
gulation vs no anticoagulation for cDVT to inform evi-
ence-based guidelines.
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Protocol and study eligibility criteria. Methodology
outlined in the Cochrane Database of Systematic Reviews9
was used to identify appropriate studies. In addition, Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA)10 and Meta-analysis Of Observational
Studies in Epidemiology (MOOSE)11 guidelines were fol-
lowed for reporting. A copy of our search protocol is
included in Appendix A, B, and C (online only). The
following inclusion criteria were specified:
1. The study design must include a control group, which
could be historic;
2. The intervention group must receive therapeutically
dosed oral, intravenous, or subcutaneous anticoagula-
tion with a vitamin K antagonist, fractionated or unfrac-
tionated heparin, or fondaparinux for a minimum dura-
tion of 1 month;
3. Controls could not receive therapeutic anticoagulation,
although prophylactic dosed anticoagulation, antiplate-
let therapy, and serial compression devices were allowed;
4. The subjects were aged 17 years, with cDVT proven
by venography or ultrasound imaging;
5. Patients with histories of clotting disorders or contrain-
dications to therapy were excluded; and
6. The minimum duration of patient follow-up had to be
30 days.
We were unable to limit the study design to random-
ized controlled trials (RCTs) because there were too few
such studies. Historic controls were included to capture as
many subjects as possible for our review. A minimum of 30
days of follow-up was used because many studies use this
measure for reporting, although the recommended dura-
tion of therapy at the time of our review was 6 weeks.
Outcomemeasures. Our primary outcome was devel-
opment of any PE, diagnosed by axial computed tomo-
graphy, conventional arteriogram, ventilation/perfusion
(V/Q) scan, or clinical criteria at 30 days (sudden unex-
plained death with antecedent leg swelling).
Secondary outcomes were divided into benefits and
harms. Benefits included detection of (1) duplex or veno-
gram evidence of proximal extension of thrombosis to the
popliteal vein, (2) postthrombotic syndrome (PTS), and
(3) reduced mortality. PTS was defined as pain, swelling, or
chronic venous insufficiency after acute treatment of the
DVT (30 days). Harms included any bleeding requiring
cessation or reversal of anticoagulation.
Search methods. We searched two electronic data-
bases, MEDLINE (1950 to October 2010) and the Co-
chrane Library (1993 toOctober 2010).We used exploded
Medical Subject Headings (MeSH) terms and key words to
generate sets for the following themes: calf, deep venous
thrombosis, and anticoagulation therapy. We used the
Boolean term “and” to find their intersection. No limits or
restrictions, including language, were used.
We conducted a manual review of references from
articles that were included in the study. To find unpub- eished studies, we reviewed abstracts from the following
cientific meetings: Society for Vascular Surgery Annual
eeting (2007 to 2010), American Venous Forum Annual
eeting (2004 to 2010), and the American College of
hest Physicians (2008 to 2010). We also searched the
linicalTrials.gov Web site (http://ClinicalTrials.gov;
000 to October 2010).
Study selection. One of two reviewers independently
creened titles and abstracts of the identified 2328 articles
rom our initial search in a nonblinded fashion. Any poten-
ially relevant articles with incomplete information by title and
bstract were screened in full text by an individual reviewer for
otential eligibility. All articles meeting inclusion criteria by
itle and abstract were reviewed in full text by two reviewers in
n independent, nonblinded fashion for final eligibility. Each
eviewer classified the articles as meets inclusion criteria or not
ased on the full text. Discrepancies were resolved by discus-
ion among all reviewers. All studies classified as meeting
nclusion criteria were then used for data extraction. Articles
ere screened for overlapping population to eliminate dupli-
ate reporting of outcomes.
Data collection. Two independent reviewers ex-
racted data from included studies using a piloted standard-
zed data abstraction form in an unblinded fashion. Dis-
repancies between reviewers were resolved by consensus
r by a third reviewer if a consensus could not be reached.
ttempts were made to contact authors of studies with
ertinent missing data. We recorded basic patient demo-
raphics, study type, intervention type, length of follow-up,
ethods of DVT and PE detection, and outcomes deter-
ined a priori on our data collection form.
Assessment of methodologic quality. The quality of
ach individual cohort study was assessed using the New-
astle-Ottawa Quality Assessment Scale (NOS) for cohort
tudies12 or the Cochrane Risk of Bias tool for RCTs.9 For
bservational studies, two independent reviewers scored
ach article on the domains of case selection, comparability,
nd outcome. The maximum score possible was 9, with 4
oints for selection, 2 points for comparability, and 3 points
or outcome. RCTs were assessed using the Cochrane Risk
f Bias tool, which contains six domains related to random-
zation, blinding, outcomes, reporting, and other potential
ources of bias.9 Each of the six aspects of methodology was
raded as yes, no, or unclear. Discrepancies between re-
iewers were resolved by consensus or by a third reviewer if
consensus could not be reached.
Analysis. All outcomes of interest were dichotomous
ariables. RevMan 5 software (Cochrane InformationMan-
gement System) was used to pool individual study results
n a weighted fashion and to compute a summary estimate
ith 95% confidence intervals (CIs) for each major out-
ome. This was done using the Peto fixed-effect model,
hich is useful when effects are small or no events are
resent in one or both arms of a study and the groups are
oughly equal in size.9 These data were then included in the
ooled odds ratio (OR) calculation for the overall summary
ffect. If the absolute numbers necessary for these calcula-
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portion of the analysis. No data were estimated.
Assessment of heterogeneity. Heterogeneity was as-
sessed for each summarized outcome using the DerSimo-
nian-Laird method, where P .1 indicated significant het-
erogeneity. Additionally, I2 index values 0.5 were
considered to represent significant heterogeneity. If signif-
icant heterogeneity was identified, the analysis was re-
peated, excluding individual studies in a sequential fashion
in an effort to identify outliers. Each summary estimate was
analyzed in two fashions: first, using all studies; second,
using only those studies that passed the test of heterogene-
ity. If we were unable to obtain homogeneity after exclu-
sion of individual studies, the pooled summary effect was
reported despite heterogeneity.
Assessment of reporting biases. Publication bias was
assessed by funnel plots, when possible, for each major
outcome. These were created by plotting the effect size
from each study against its respective sample size. Funnel
plots were then visually inspected for symmetry.
Subgroup analyses. Because monitoring and ensur-
ing therapeutic levels of anticoagulation may be variable
based on the type of anticoagulation used and the provider,
we performed a subgroup analysis examining the relation-
Fig 1. Preferred Reporting Items for Systematic Review
through the phases of the systematic review of patients w
excluded in full text based on failure to fulfill the inclusio
duplex ultrasound-proven peroneal or tibial DVT; (2) co
ulation treatment for isolated calf DVT; (3) interventi
low-molecular-weight heparin, or fondaparinux for at lea
anticoagulation; (5) minimum follow-up was 30 days; an
included.ship between PE and treatment of distal venous thrombosis 2ith anticoagulation that was documented to be within
herapeutic range for 80% of the patients’ treatment
ourse. For the purposes of our study, therapeutic antico-
gulation was defined as an international normalized ratio
f 2 to 3 or partial thromboplastin time 1.5, the upper
imit of normal; if not defined, a value of 90 to 140 was
onsidered therapeutic.
Sensitivity analyses. Several sensitivity analyses were
erformed. First, we limited the results to RCTs only.
hen, we limited the results for each element of theNOS to
valuate the effect of various methodologic parameters on
ur results. We then performed an additional sensitivity
nalysis to examine the effect of duration of anticoagulation
herapy (6 vs 6 weeks) on our primary outcomes.
ESULTS
Description of studies. We identified 2325 potential
tudies from the Cochrane Library and MEDLINE searches.
wo additional studies that met inclusion criteria were iden-
ified in ClinicalTrials.gov; however, neither study was in-
luded in the analysis because they are both currently recruit-
ng subjects. By reviewing meeting abstracts and relevant
eferences, we identified three additional studies for potential
nclusion. After duplicate studies were removed, we excluded
Meta-Analyses (PRISMA) flow diagram of information
lated calf vein deep venous thrombosis (DVT). Articles
teria: (1) patients 17 years of age with venographic or
ative study of anticoagulation treatment vs no anticoag-
roup received therapeutically dosed heparin, warfarin,
days; (4) control group did not receive any therapeutic
article contained duplicate data as another series alreadys and
ith iso
n cri
mpar
on g
st 30
d (6)121 articles by title and abstract screening. The remaining
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Volume 56, Number 1 De Martino et al 231185 articles were reviewed in full text. Eight studies met full
inclusion criteria (Fig 1).
Included studies. Eight studies, consisting of 505
patients, were included in our review: two were RCTs,
three were retrospective cohort studies, two were prospec-
tive cohort studies, and one was a combined retrospective
and prospective cohort study. All studies occurred between
1985 and 2007 and consisted primarily of medical and
surgical inpatients. One study was performed in an ambu-
latory setting and one study had a mixture of hospitalized
and ambulatory patients. Study size ranged from 16 to 193,
with a mean patient age of 55 to 70 years. Intervention
patients were treated with vitamin K antagonist alone (one
study), unfractionated heparin alone (one study), or com-
binations of vitamin k antagonists plus heparin (six studies).
Table I. A, Characteristics of included studies
Author Year Study design
Lagerstedt3 1985 RCT Medical
Pellegrini4 1993 Prospective
(nested)
Post-op
proph
DVT
Nielson13 1994 RCT Inpatien
Dorr14 2007 Retrospective Post-op
Masuda15 1997 Retrospective and
prospective
Outpatie
Solis16 1992 Retrospective Orthope
evalua
Lohr17 1995 Prospective NS; inpa
Sachdev18 2006 Retrospective Rehab p
proph
DVT, Deep venous thrombosis; ND, no data; NS, not specified; RCT, rand
Table I. B, Characteristics of included studies
Author Year Intervention
Duration
(months)
Lagerstedt3 1985 IV heparin for 5 days
plus warfarin
3 IV he
com
Pellegrini4 1993 Warfarin 1.5 SCDs
Nielson13 1994 IV heparin plus
phenprocoumon
3 Pheny
day
Dorr14 2007 LMWH or warfarin 3-6 Aspiri
clop
Masuda15 1997 IV heparin for 5 days
plus warfarin
3 Not sp
Solis16 1992 Warfarin; IV heparin;
or LMWH at
therapeutic dose
ND Proph
hep
Lohr17 1995 IV heparin 1 SCDs
dipy
pro
Sachdev18 2006 Warfarin; IV heparin;
or LMWH
ND Proph
ASA, Acetylsalicylic acid; DVT, deep venous thrombosis; IV, intravenous
pulmonary embolism; SCD, sequential compression device; V/Q, ventilatioFollow-up ranged from 1 to 12 months (Table I). gPulmonary embolus. Five homogeneous studies, in-
luding 209 patients, reported rates of PE for both the
nticoagulation and control arms (P  .87, I2  0%). The
ummary effect demonstrated significantly lower rates of
E in patients treated with anticoagulation than in controls
OR, 0.12; 95% CI, 0.02-0.77; Fig 2). The diagnosis of PE
as made by V/Q scan in four studies. In the remaining
tudy, combinations of V/Q scans, pulmonary angiogra-
hy, and clinical presentation were used to make the diag-
osis of PE. Two PEs were made by clinical diagnosis.
hese two patients experienced sudden, unexplained death
aused by a cardiopulmonary event that was preceded by
rogressive leg swelling with documented DVTs.4
Proximal thrombus progression. Six studies with
19 patients reported results of proximal thrombus pro-
Population No.
Age
(years)
Male sex
(%)
ients 51 62.8 56.9
ts in RCT to evaluate
c warfarin vs SCDs for
25 63.7 ND
itted for DVT 16 55 64.4
ts 45 64.9 43
en in clinic 46 64 43
rgery patients in study to
phylaxis for DVT
42 70 35.7
and outpatients 193 56.8 42
s in study to evaluate
for DVT
87 64.7 50
d controlled trial; SCD, sequential compression device.
parison
Detection method
Follow-up
durationPE DVT
for 5 days and
ion hose
V/Q scan Venogram 6 weeks
V/Q scan, clinical
diagnosis
Venogram 6 weeks
zone for 9 V/Q scan Venogram 6 weeks
yridamole,
rel
V/Q scan Ultrasound 6 weeks
d V/Q scan Ultrasound 6 weeks
c dextran,
or warfarin
NS Venogram,
ultrasound
6 weeks
,
ole,
ctic warfarin
V/Q scan Ultrasound 6 weeks
c heparin NS Ultrasound 6 weeks
H, low-molecular-weight-heparin; ND, no data; NS, not specified; PE,
fusion.inpat
patien
ylacti
ts adm
patien
nts se
dic su
te pro
tients
atient
ylaxisCom
parin
press
lbuta
s
n, dip
idog
ecifie
ylacti
arin,
, ASA
ridam
phyla
ylacti
; LMWression and were homogeneous (P .15, I2  38%). The
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imaging alone (three studies), venography alone (two stud-
ies), and a combination of duplex and venography (one
study). As with PE, the summary effect showed a significant
reduction in thrombus propagation among patients treated
with anticoagulation compared with those not receiving
anticoagulation (OR, 0.29; 95% CI, 0.14-0.62; Fig 3).
Postthrombotic syndrome. One study3 reported
data pertaining to PTS. Eight control patients had DVT
recurrence and had higher pain scores than treated patients.
Of patients without recurrence, 56% reported no pain at 14
days of follow-up, and 93% reported no pain by 90 days.
Fig 2. Rates of pulmonary embolus (PE) among treat
thrombosis (DVT). CI, Confidence interval.
Fig 3. Rates of thrombus propagation to the popliteal v
deep venous thrombosis (DVT). CI, Confidence interva
Fig 4. Mortality rates among treated and control patien
Confidence interval.The remaining seven studies did not present PTS data. aMortality. Four of the included studies reported ab-
olute mortality rates for the anticoagulation and control
rms. The combined summary effect from these studies
emonstrated no difference in mortality rates between pa-
ients who were and were not anticoagulated (OR, 0.57;
5% CI, 0.06-5.66; Fig 4). However, these studies were
eterogeneous (P  .09, I2 66%). Quantitative interpre-
ation revealed that mortality rates overall were low in the
ncluded studies and did not favor the intervention or the
ontrol arm.
Bleeding requiring cessation or reversal of therapy.
our studies reported results for adverse bleeding effects of
d control patients with isolated calf vein deep venous
ong treated and control patients with isolated calf vein
h isolated calf vein deep venous thrombosis (DVT). CI,ed anein amts witnticoagulation. The data from these studies were hetero-
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Volume 56, Number 1 De Martino et al 233geneous (P .02, I2 82%). The summary effect of these
combined studies demonstrated no statistical difference in
bleeding events in the anticoagulation and control arms
(OR, 1.60; 95% CI, 0.21-12.36; Fig 5).
Subgroup analysis: documented vs unspecified
therapeutic anticoagulation. Two studies reported data
confirming that most patients who received anticoagula-
tion were within the therapeutic range during the study
period.3,13 The remaining studies did not provide data to
document adequacy of anticoagulation.4,14-18 One of the
two studies that provided documentation to support ther-
apeutic anticoagulation also reported absolute rates of PE.
There was no difference in the rate of PE between this study
and the remaining studies that did not document therapeu-
tic anticoagulation, with ORs for PE of 0.16 (95% CI,
0.00-8.31) vs 0.12 (95% CI, 0.02-0.77). Both studies
documenting therapeutic anticoagulation reported rates of
thrombus progression. There was no difference between
the pooled rate of thrombus progression between this
subgroup and the subgroup of studies that did not report
efficacy of anticoagulation, with ORs for thrombus progres-
sion of 0.14 (95% CI, 0.02-0.87) vs 0.34 (95% CI, 0.15-
0.77). Mortality results were unchanged based on subgroup
analysis. In studies reporting therapeutic anticoagulation,
there appeared to be an increase in bleeding events compared
with those not reporting anticoagulation, with anOR of 21.7
(95% CI, 1.1-424.7) vs 0.16 (95% CI, 0.01-2.6).
Sensitivity analyses. From the results of an RCT
that demonstrated 6 weeks of anticoagulation was suffi-
cient for the treatment of calf vein DVT,19 we dichoto-
mized included studies into those that treated patients
for6 weeks or6 weeks. Sensitivity analysis performed
by treatment length showed no change in the pooled
effect for PE, thrombus propagation, or death. The
pooled summary effect for bleeding changed to favor
anticoagulation treatment but was not significant (OR,
0.16; 95% CI, 0.01-2.6, P .2).
Sensitivity analysis was also performed by methodo-
logic quality. When only randomized trials were selected,
reduction in thrombus propagation with anticoagulation
remained statistically significant. Prevention of PE was fa-
vored by anticoagulation but was not statistically significant
(OR, 0.16; 95% CI, 0.0-8.31). Sensitivity analysis was
Fig 5. Bleeding rates among treated and control patien
Confidence interval.performed by each component of the NOS. Our finding of ohrombus propagation was robust and only affected by
nalysis by adequacy of follow-up, and PE was sensitive to
ethods of assessment.
Methodologic quality of included studies. Overall,
ncluded studies had poor to moderate methodologic qual-
ty. The two RCTs were not blinded, and the randomiza-
ion had inadequate sequence generation (Fig 6). The six
emaining observational studies had a meanNOS score of 5
range, 4-7). Demonstration that the outcome of interest
as not present at baseline and adequacy of follow-up were
he most frequent missing items (Table II).
Assessment for publication bias. Thrombus pro-
ression was the only outcome with enough studies to
reate a funnel plot for evaluation of publication bias. On
isual inspection, it appears that a bias is present for studies
h isolated calf vein deep venous thrombosis (DVT). CI,
ig 6. Cochrane Risk of Bias tool for randomized controlled
rials. Green (), Low risk of bias; yellow (?), unclear from the
tudy; red (–), high risk of bias.ts witbserving a treatment effect (Fig 7).
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Clinicians struggle to balance the morbidity and mor-
tality from thromboembolic complications after isolated
cDVT with the risks of anticoagulation. The current study
attempts a systematic appraisal of the available literature
concerning comparative anticoagulation treatment for
cDVT. Our findings suggest that treatment of cDVT with
anticoagulation may result in a significant reduction in occur-
rence of PE and proximal thrombus propagation. However,
although the outcomes of bleeding and mortality weakly
favored the controls in our analysis, the data available are not
robust enough to make any inference regarding the potential
harms of anticoagulation. Subgroup and sensitivity analysis
did not have any effect on our findings.
The treatment of cDVT has been extensively debated in
prior reviews without reaching clear consensus.2,20-23 This
debate stems from the lack of empiric knowledge about the
Table II. Newcastle-Ottawa Quality Assessment Scale for
Study
Selection
Representativeness
of the exposed
cohort
Selection of
the
nonexposed
cohort
Ascertainment
of exposure
A
Dorr14 2007  – 
Lohr17 1995   
Masuda15 1997   
Pellegrini4 2003   
Sachdev18 2006   
Soils16 1992   
Selection: (1) Representativeness of the exposed cohort: if truly or somewhat
of the nonexposed cohort:if drawn from the same community as the exposed
(4) Absence of outcome at baseline: if demonstration that outcome of inter
Comparability: Comparability of cohorts on the basis of the study design or an
additional risk factors (such as age or thrombophilia).
Outcome: (1)Assessment of outcomes:if independent blind assessment or re
occur; (3) Adequacy of follow-up of cohorts:if all subjects completed follow
follow-up).
Fig 7. Funnel plot of studies reporting clot propagation. OR,
Odds ratio.true risk and natural history of cDVT. Proponents of anti- hoagulation for cDVT argue that the incidence of PE from
DVT alone warrants treatment.3,24 However, opponents
uggest that this rate is low, and that even surrogate points,
uch as propagation of thrombus, do not meet clinically
mportant cutoffs for treatment.2,21 Unlike the current
tudy, prior reviews20,22 did not search the literature in a
ystematic fashion, thus introducing potential selection,
eporting, and publication bias, as suggested by the Co-
hrane Collaboration for Systematic Reviews.9 Further,
rior reviews did not adhere to proposed standards for
eviews of observational studies,11 including assessment of
he methodologic quality.
This study has incorporated all such efforts to derive the
ost objective assessment of treatment efficacy. However,
espite our systematic efforts to compile the current litera-
ure and generate a pooled effect, many included studies
ailed to analyze and report the full spectrum of potential
reatment benefits and harms, making an objective assess-
ent difficult. Overall, our findings are similar to those of
rior reviews in PE rates and thrombus propagation.20,22
n general, patients treated with anticoagulation have few if
ny thromboembolic events, whereas patients who remain
ntreated experience a variable but low rate of events.
Although our meta-analysis found a significant reduc-
ion in the rate of PE treated with anticoagulation for
solated cDVT, we believe it is important to place the results
f our meta-analysis in context. Few of the studies included
n our analysis were designed to address our research ques-
ion directly. Many were investigating the relationships
etween anticoagulation therapy and the treatment of any
VT (including proximal),14 PE,13 or duplex surveil-
ance.16,18 Therefore, we extracted data pertinent to our
eview from these larger populations, resulting in a small
umber of included patients (n 200) and a very low event
ate overall (n  5). In addition, although our sensitivity
nd subgroup analysis was limited, it revealed that PE was
ervational Studies
Comparability
Outcome
ce of
me
ine
Assessment
of outcome
Length of
follow-up
Adequacy of
follow-up Total score
–   – 4
–   – 5
   – 4
–    6
– – – – 5
  –  7
sentative of the average patient with deep venous thrombosis; (2) Selection
rt; (3) Ascertainment of exposure:if secure record or structural interview;
s not present at start of study.
if study controls for comorbidities; additional if study controls for any
inkage; (2) Length of follow-up:if follow-up long enough for outcomes to
r subjects lost to follow-up unlikely to introduce bias (small number lost toObs
bsen
outco
at
basel
–
–
–
–

–
repre
coho
est wa
alysis:
cord lighly determined by the included studies in the pooled
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Volume 56, Number 1 De Martino et al 235estimate. For these reasons, we believe the data pertaining
to PE are not robust and should be used cautiously when
informing clinical decision making.
Alternatively, we believe that the quality of the evidence
to support anticoagulation for reduction of thrombus propa-
gation is adequate. This is due to higher event rates and a
larger number of patients present in the pooled estimate. In
addition, this finding was more robust under sensitivity anal-
ysis. Prevention of thrombus propagation is important be-
causemore proximal thrombus carries increased thromboem-
bolic risk and a potentially higher risk of PTS.
Interestingly, more than half of the studies included in
this review failed to specify the rates of clinically significant
bleeding associated with treatment.14,15,17,18 This omis-
sion is mirrored in other reviews2,20,23 and limited our
ability to derive a reliable pooled estimate for the effect of
anticoagulation on this outcome. Treatment with a vitamin
K antagonist or heparin may result in major bleeding in 3%
to 5% of patients per year.25 Although the risk of short-term
therapy may be less, initiation of anticoagulation represents
a tangible bleeding risk that must be considered in future
trials of anticoagulation therapy for cDVT.
Lastly, only one study reported sequelae of PTS from prior
cDVT despite our attempts to capture this outcome. Prior re-
ports suggest that 23% to 33% of patients with cDVT may
developPTS.26-28This is a severe limitation toprior comparative
studies concerning the treatment of cDVTwith anticoagulation
therapy that requires further investigation.
Our study has several limitations. First, as noted, qualita-
tive and quantitative assessment of included studies both
revealed that the overall methodologic quality of these studies
was low.WithinRCTs, issues surrounding adequate sequence
generation, blinding, and selective reporting make conclu-
sions drawn less robust. Among the included observational
studies, major drawbacks in methodology revolved around
verifying that the outcomes were not present at the beginning
of the study and inadequate follow-up for outcome identifi-
cation. We are most concerned by the latter, because a lack of
appropriate follow-up may underestimate true event rates.
Many of the studies performed follow-up venography or
ultrasound imaging in only 75% patients, allowing for poten-
tial bias in the incidence of thrombus propagation.13,16,18
Despite themethodologic flaws of individual included studies,
our review is strengthened because our results were consistent
in outcomes across trials.
Second, we did not have standardized criteria for control
status of subjects, and the management of controls varied be-
tween studies. Included control therapies ranged from antiplate-
let agents to sequential compression devices, prophylactic hepa-
rin, or a combinationof these.However,webelieve that this only
strengthensourfindings, assumingthat theseagents areexpected
to minimize event rates in the control arm.
Despite using protocols derived fromCochraneHandbook
for Systematic Reviews,9 our search and analysis had several
limitations. First, our search involved twomajor electronic data-
bases, but access to other databases, such as EMBASE, was not
available.However, searches of both EMBASE andMEDLINE Cave been found to contain similar overlapping content and
eturn similar numbers of relevant references.
In addition, although 10 studies are desirable for a
eta-analysis, our systematic search was only able to iden-
ify eight studies that directly compared treated and control
atients. Although there are additional studies that have
nvestigated treatment of cDVT, they did not fully meet
ur inclusion criteria intended to minimize bias.
Lastly, although a useful statistic, we did not include a
alculation of number needed to treat in our review. Calcula-
ions performed using the relatively weak data extracted from
hese studies may be a misrepresentation of the truth. This
ay give the impression that the data reflect a level of precision
hat is yet present in the current literature.
Although anticoagulation appears to successfully re-
uce proximal thrombus propagation in patients with iso-
ated cDVT, the effects of this therapy on the risk of PE are
ess unclear. Further, it is unknown whether the harms
ssociated with anticoagulation therapy outweigh the po-
ential benefits. Properly designed prospective randomized
tudies are necessary that compare anticoagulation treat-
ent vs control with assessment of PE, clot propagation,
leeding events, death, and follow-up long enough to
dequately assess PTS.
Presently, the Contention Alone vs Anticoagulation for
ymptomatic Calf Vein Thrombosis Diagnosed by Ultra-
onography (CACTUS) trial (registered at http://clinicaltri-
ls.gov, identifiers NCT00421538 and NCT00539058) is
urrently active in Europe to attempt to answer this clinical
uestion. The protocol for the CACTUS trial compares 6
eeks of low-molecular-weight heparin, nadroparin, and
ompression stockings vs placebo and compression stock-
ngs on proximal propagation of cDVTs. PE is listed as a
econdary outcome of this study.
ONCLUSIONS
Our review suggests that anticoagulation therapy for
DVT significantly reduces proximal thrombi propagation.
n the basis of existing data, we cannot comment on the
ffects of anticoagulation for clinically important outcomes
uch as PE, death, and bleeding. Clinicians should incor-
orate a patient’s known risk factors for venous thrombo-
mbolic events and bleeding risk when determining
hether to treat patients with cDVT. A rigorous, random-
zed controlled study is needed to assist clinicians by guid-
ng treatment decisions for isolated cDVT.
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Dr Joseph Ricotta (Atlanta, Ga). How long were these
patients anticoagulated for? Was there variability between the
studies in terms of the duration of anticoagulation therapy?
Dr Randall R. De Martino. There was some variation. We
required a minimum of 30 days because most of these were
postoperative patients and that is what reporting goes to, although
I think treatment should last for at least 6 weeks. We did a
sensitivity analysis of outcomes by studies reporting 6 weeks of
anticoagulation treatment or less. There was no change in the
effect on clot propagation or PE.
Dr Ricotta. The longer the duration?
Dr De Martino. Correct.oleus plexus clots in the absence of the named tibial vessel
lots?
DrDeMartino.We did not look specifically at gastrocnemius
r soleal clots in this study. We were focused on tibial and peroneal
hrombi. I think that they may follow a similar pattern, although
e can’t make any conclusions based on this study. Other studies
hat have addressed that question and maybe a compilation of
hose studies can help identify if they are similar in characteristics.
ut I don’t know that the clinical history of them is as well defined
s is tibial and peroneal.
Dr Firas Mussa (New York, NY). Your last bullet suggests
uture studies. Can you elaborate on design of those studies?Dr De Martino. I think there is still clinical equipoise as to
hether or not we can treat or not treat these patients. Based on
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Volume 56, Number 1 De Martino et al 237the data and the studies that are available, I think that there is still
a debate about this. I think clinical randomized trials will need to
assess the benefits and the harms of treatment, including bleeding,
mortality rates, and post-thrombotic syndrome. I am aware of one
ongoing clinical study in Europe, but I am unaware of the current
enrollment status. I was told yesterday in discussion, the University
of Washington has applied for a grant to perform a randomized
trial for this, and we hope that that will be funded and shed light on
this topic.
Dr Cynthia Shortell (Durham, NC). It is no surprise that
anticoagulation prevents thrombotic complications of calf vein
clot. The question has always been, when is the risk of anticoagu-
lation worth the benefit? And in calf vein thrombosis, that issue
gets down to what the risks of those patients are. One would intuit
that high-risk patients with calf clots, such as neurosurgical patients
or immobile patients, would be at higher risk, but that’s unknown
at this point. Did any of the studies that you included contain that
information? And if so, do you think you could use it to help us
identify those patients with calf clot that would really benefit from
anticoagulation?
Dr De Martino. I think we agree that there are patients who
are at higher risk. Several of these studies did try to identify specific
risk factors that would identify those patients with thrombi that are
going to propagate or cause PE. The most consistent risk factor
identified was inpatient status. Many other patient-level variables
that they were able to analyze were not predictive in their analyses.
We didn’t include that type of review in the present study, but that
is what I have been able to extract from the data that is available to
date.
DrMarkMeissner (Seattle, Wash). I was somewhat surprised
that although bleeding was heterogeneous, pulmonary embolism
and thrombus propagation was remarkably homogeneous. I think
this is surprising, because perhaps even more so than with proximal
vein thrombosis, calf vein thrombosis is often perceived to be a
heterogeneous disease with the risk of complications based on the
underlying risk factors for thrombosis. Your analysis seems to imply
that all calf vein thrombi should be treated as equal, which may not
be correct. Can you explain the homogeneity of your findings?
Dr De Martino: In regards to PE and clot propagation, I
think our pooled summary was homogeneous because of our strict
entry criteria. There are other studies reported on calf DVT that
were excluded because they didn’t meet this criteria. I think that
helped in creating a homogeneous estimate.
i
oThemajority of studies did report on PE and clot propagation.
ery few studies reported bleeding andmortality complications, so
he data that we were able to extract were sparse and spread across
ight studies, where only two to three may have contributed to the
ata, and I think that that affected our ability to make a homoge-
eous summary effect.
I think that while we were able to make a homogeneous study
ffect, we acknowledge that the strength of our findings comes
rom the quality of the studies that they were derived from. And so
robust clinical trial will really answer this question in the best light
ossible.
Dr Peter Gloviczki (Rochester, Minn). Did you notice a
ifference in symptomatic and asymptomatic calf vein thrombosis,
r were all these patients symptomatic?
Dr De Martino. We didn’t perform a formal subgroup anal-
sis of studies that were symptomatic or asymptomatic. Approxi-
ately half of the studies identified their patients as symptomatic,
wo of those four being the randomized controlled trials. But we
re unable to make a comment about whether the symptomatic
tatus does make a difference.
DrGloviczki.Andwas the diagnosis of PEmade using similar
echniques in these studies?
DrDeMartino.The diagnosis of PE was similar in all but one
tudy, which used a combination of V/Q scan and clinical diagno-
is based on patients with a sudden death that was preceded by
apid leg swelling. And so it was felt that that was a clinical
iagnosis of PE and we did include that.
Dr Roger Shinnerl (Evansville, Ind). I was wondering if you
ould please tell me if I am wrong, but I was left with the distinct
mpression, after looking at your data briefly, that all of the positive
esults were out of one study, the Pellegrini study. And that
isturbs me. Does that not make that study an outlier? And even if
ot, should we really be endorsing that finding with the results of
pooled analysis?
Dr De Martino. That one study was a nested case-control
tudy within a randomized trial. While they did identify a lot of
utcomes, I do not think that their methods were any different
han the other randomized trial that would make me think that
hey should be excluded or be an outlier. I think the fact that
ur summary of facts remained homogeneous despite their
nclusion attests that it was appropriate to include them within
ur analysis.
A
p
S
o
o
o
o
o
o
o
o
o
o
o
o
o
o
A
l
#
#
#
#4 (#1 and #2 and #3)
JOURNAL OF VASCULAR SURGERY
July 2012237.e1 De Martino et alAppendix A (online only). MEDLINE search protocol
(1950-2010), last searched Oct 19, 2010
Search Term(s)
#1 Venous thrombosis
#2 DVT
#3 Thrombosis
#4 #1 or #2 or #3
#5 Leg
#6 Calf
#7 Tibial
#8 Crural
#9 Below knee vein
#10 #5 or #6 or #7 or #8 or #9
#11 #4 and #10
#12 Calf vein thrombosis
#13 Tibial vein thrombosis
#14 Crural vein thrombosis
#15 Below knee vein thrombosis
#16 #11 or #12 or #13 or #14 or #15
#17 Anticoagulation
#18 Coumadin
#19 Warfarin
#20 Heparin
#21 Low-molecular-weight heparin
#22 Enoxaparin
#23 Fondaparinux
#24 Dalteparin
#25 Tinzaparin
#26 Anticoagulants
#27 #17 or #18 or #19 or #20 or #21 or #22 or
#23 or #24 or #25 or #26
o#28 #16 and #27ppendix C (online only). ClinicalTrials.gov search
rotocol, last searched Oct 18, 2010
earch terms: anticoagulation and deep venous thrombosis |
venous thrombosis
r DVT
r thrombosis
r “calf vein thrombosis”
r “tibial vein thrombosis”
r “crural vein thrombosis”
r “below knee vein thrombosis” | anticoagulation
r Coumadin
r warfarin
r heparin
r “low molecular weight heparin”
r enoxaparin
r fondaparinux
r Dalteparin
r tinzaparinppendix B (online only). Cochrane search protocol,
ast searched Oct 19, 2010
Search Term(s)
1 (Deep vein thrombosis) or (DVT) or (venous
thrombosis) or (thrombosis)
2 Calf or below knee or infrageniculate
3 Anticoagulation or warfarin or Coumadin or heparinr anticoagulants
